ATQP.F Vericel Corporation

Healthcare Biotechnology Frankfurt Exchange
53.00 EUR
Close of Nov 11, 2026
25.40 53.00
Market cap
EUR 2.70B
P/E
89.8x
P/B
7.68x
ROE
3.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is ATQP.F undervalued?

Graham number

The Graham number of Vericel Corporation cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Vericel Corporation fundamental analysis

No fundamental analysis for Vericel Corporation yet.

Vericel Corporation stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Vericel Corporation

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects o…

Full company profile